The role of central and peripheral mu opioid receptors in inflammatory pain and edema: a study using morphine and DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid).
The role of opioid receptors located in the central nervous system (CNS) and peripheral nervous system in inflammatory pain is well established. In contrast, although it is has been shown that mu agonists can reduce other manifestations of inflammation, such as edema, the mechanism of action remains unclear. In this study, we have activated mu receptors located centrally, those located peripherally, and those located both centrally and peripherally and compared the effects on pain and edema using the rat carrageenan model of acute inflammation. Activation of mu receptors located only in the periphery, by administration of the peripheralized mu agonist [8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid (DiPOA) or local administration of morphine, resulted in antihyperalgesia (30 mg/kg DiPOA, 83% inhibition; 100 microg/rat morphine, 75% inhibition) without affecting edema. In contrast, activation of both central and peripheral mu receptors using systemically administered morphine resulted in antihyperalgesia (1 mg/kg, 80% inhibition) and inhibition of edema (10 mg/kg, 54% inhibition). Finally, activation of only receptors located in the CNS, by central administration of DiPOA or systemic administration of morphine after block of only the peripheral mu receptors using q-naltrexone, resulted in a significant reduction in edema. Our findings confirm the role of peripheral mu receptors in the pathology of pain associated with acute inflammation and argue against the involvement of these receptors in edema formation. Furthermore, our data demonstrate that activation of mu receptors in the brain inhibits carrageenan-induced edema and suggest that the antiedematous effect of morphine is due to action at central receptors alone.
Whiteside
Garth T
GT
Purdue Pharma Discovery Research, Cranbury, New Jersey, USA. garth.whiteside@pharma.com
Boulet
Jamie M
JM
Walker
Katharine
K
D000085:Acetates / Q000494:pharmacology*; D000818:Animals; D001372:Aza Compounds / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D002351:Carrageenan; D004487:Edema / Q000209:etiology*; D007276:Injections, Intraventricular; D008297:Male; D009020:Morphine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D009271:Naltrexone / Q000494:pharmacology; D010146:Pain / Q000209:etiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017450:Receptors, Opioid, mu / Q000187:drug effects / Q000502:physiology*; D013141:Spiro Compounds / Q000494:pharmacology*
C498149:(8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro(4.5)dec-3-yl)-acetic acid; D000085:Acetates; D001372:Aza Compounds; D017450:Receptors, Opioid, mu; D013141:Spiro Compounds; D009271:Naltrexone; D009020:Morphine; D002351:Carrageenan